Flash e-reader

 Go to e-reader chapter








Table 15.7

Immunosuppression Use for Maintenance by Regimen

Two Years Following Transplantation, 1999 to 2007

Recipients with Kidney Transplants

  Transplant Year
1999 2000 2001 2002 2003 2004 2005 2006 2007
Transplants 12,765 13,620 14,276 14,779 15,137 16,006 16,483 17,095 16,634
Functioning Graft at 2 Years PostTx 10,225 11,064 11,837 12,311 12,633 13,388 13,767 14,550 14,340
With Maintenance Use Recorded at 2 Years PostTx 9,705 10,831 11,529 11,993 12,344 13,041 11,104 10,795 10,371
CyA 0.7% 0.2% 0.2% 0.1% 0.1% 0.1% 0.1% 0.2% 0.1%
Tac 0.8% 0.8% 1.5% 1.8% 1.9% 2.3% 3.1% 3.1% 2.6%
--- + MMF/MPA 0.1% 0.1% 0.1% 0.1% 0.3% 0.3% 0.3% 0.2% 0.2%
CyA + MMF/MPA 1.1% 1.4% 1.5% 1.7% 2.3% 2.3% 2.1% 1.6% 1.5%
Tac + MMF/MPA 2.2% 2.9% 4.4% 6.5% 9.9% 15.5% 22.1% 26.0% 27.5%
--- + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet 0.2% 0.1% 0.1% 0.1% 0.0% 0.1% 0.1% 0.0% 0.0%
Tac + OtherAntimet 0.2% 0.2% 0.2% 0.3% 0.2% 0.3% 0.4% 0.6% 0.7%
--- + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Siro/Evero 0.0% 0.2% 0.3% 0.2% 0.1% 0.2% 0.2% 0.2% 0.1%
CyA + Siro/Evero 0.2% 0.3% 0.4% 0.8% 0.8% 0.8% 1.0% 0.8% 0.8%
Tac + Siro/Evero 0.1% 0.9% 2.1% 2.4% 2.7% 2.1% 1.6% 1.0% 0.7%
--- + MMF/MPA + Siro/Evero 0.0% 0.2% 0.5% 0.7% 1.4% 1.9% 2.4% 2.5% 2.0%
CyA + MMF/MPA + Siro/Evero 0.0% 0.1% 0.1% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0%
Tac + MMF/MPA + Siro/Evero 0.1% 0.2% 0.3% 0.5% 0.8% 0.7% 0.8% 0.6% 0.7%
--- + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Steroids 0.7% 0.3% 0.5% 0.4% 0.5% 0.2% 0.2% 0.2% 0.2%
CyA + Steroids 6.9% 4.1% 2.4% 1.5% 1.4% 0.9% 0.7% 0.5% 0.6%
Tac + Steroids 7.2% 7.4% 6.5% 6.1% 5.1% 4.5% 4.4% 4.7% 5.2%
--- + MMF/MPA + Steroids 2.0% 1.4% 1.3% 1.3% 1.1% 1.2% 1.1% 0.9% 0.7%
CyA + MMF/MPA + Steroids 36.3% 31.0% 22.8% 18.5% 14.0% 12.1% 7.4% 5.1% 4.3%
Tac + MMF/MPA + Steroids 27.3% 29.7% 35.0% 38.6% 41.3% 40.0% 40.4% 41.0% 43.2%
--- + OtherAntimet + Steroids 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%
CyA + OtherAntimet + Steroids 4.6% 2.9% 1.5% 0.7% 0.5% 0.3% 0.2% 0.1% 0.2%
Tac + OtherAntimet + Steroids 2.1% 2.0% 2.0% 1.6% 1.4% 1.3% 1.3% 1.6% 1.6%
--- + Siro/Evero + Steroids 0.5% 0.7% 1.0% 0.7% 0.9% 0.9% 0.8% 0.5% 0.5%
CyA + Siro/Evero + Steroids 2.3% 3.7% 2.9% 2.5% 1.9% 1.4% 1.1% 1.0% 1.1%
Tac + Siro/Evero + Steroids 1.3% 4.8% 6.5% 5.6% 4.4% 3.2% 2.3% 1.8% 0.9%
Other Regimen 3.0% 4.2% 5.8% 6.9% 6.7% 7.1% 5.7% 5.3% 4.2%


Source: OPTN/SRTR Data as of October 1, 2010.

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.